FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1514558457> ?p ?o ?g. }

• W1514558457 endingPage "168" @default.
• W1514558457 startingPage "157" @default.
• W1514558457 abstract "Background: Most results on the treatment of chronic myeloid leukaemia (CML) with imatinib were obtained from clinical trials that may differ from the routine practice. We report the results of treatment of consecutive patients with CML at ten major centres during 2000–2008. Patients and methods: Data reporting was retrospective in 2000–2004 and prospective from 2005 on. A total of 661 patients [301 women and 360 men; median age 51 (range, 15–83)] with Ph + CML were registered. The median follow-up was 46.1 months (0–122.2). Results: Most patients were treated with first- (379; 57.3%) or second-line (193; 29.2%) imatinib; some of the patients underwent allogeneic hematopoietic stem cell transplantation (AHSCT) (83; 12.6%), but 6.1% were treated with other modalities [40 patients; median age 66 (range, 32–83)]. The probability of overall survival (OS) at 5 years, according to Kaplan and Meier, was 88.9%, 77.5% and 68.7% for chronic-phase patients treated with first-line imatinib, second-line imatinib and first-line AHSCT, respectively, but only 25.2% for patients receiving other modalities. The OS was dependent on the disease phase and Sokal, Hasford and European group for blood and marrow transplantation (EBMT) risk scores (P < 0.001; each). Only 46.2% of deaths in patients treated with other modalities were attributable to CML. Elderly patients over 65 years achieved similar response rates and progression-free survival to the younger ones. There was a trend for inferior results of AHSCT performed after the failure of imatinib (P = 0.075), probably as a result of differences in EBMT risk scores (P < 0.001). Conclusions: The ability to achieve results comparable to those of previous clinical studies in our CML cohort was influenced by centralised care. Decisions not to initiate imatinib or to delay AHSCT may have a negative impact on OS, but comorbidities may limit the treatment potential of imatinib in the elderly." @default.
• W1514558457 created "2016-06-24" @default.
• W1514558457 creator A5003934490 @default.
• W1514558457 creator A5015364051 @default.
• W1514558457 creator A5015623446 @default.
• W1514558457 creator A5027543943 @default.
• W1514558457 creator A5031444581 @default.
• W1514558457 creator A5031769736 @default.
• W1514558457 creator A5034008882 @default.
• W1514558457 creator A5037131671 @default.
• W1514558457 creator A5045455980 @default.
• W1514558457 creator A5046844133 @default.
• W1514558457 creator A5060416371 @default.
• W1514558457 creator A5064549322 @default.
• W1514558457 creator A5084596816 @default.
• W1514558457 creator A5090042377 @default.
• W1514558457 date "2011-07-15" @default.
• W1514558457 modified "2023-10-18" @default.
• W1514558457 title "Treatment of consecutive patients with chronic myeloid leukaemia in the cooperating centres from the Czech Republic and the whole of Slovakia after 2000 - a report from the population-based CAMELIA Registry" @default.
• W1514558457 cites W1978269924 @default.
• W1514558457 cites W1994571536 @default.
• W1514558457 cites W2015077893 @default.
• W1514558457 cites W2016953305 @default.
• W1514558457 cites W2023486961 @default.
• W1514558457 cites W2025681750 @default.
• W1514558457 cites W2028959752 @default.
• W1514558457 cites W2036862498 @default.
• W1514558457 cites W2042528156 @default.
• W1514558457 cites W2070067474 @default.
• W1514558457 cites W2085609147 @default.
• W1514558457 cites W2107268345 @default.
• W1514558457 cites W2117806883 @default.
• W1514558457 cites W2120021574 @default.
• W1514558457 cites W2120756704 @default.
• W1514558457 cites W2128177827 @default.
• W1514558457 cites W2151486690 @default.
• W1514558457 cites W2157436488 @default.
• W1514558457 cites W2158884958 @default.
• W1514558457 cites W2563652742 @default.
• W1514558457 cites W2587781815 @default.
• W1514558457 cites W3041047318 @default.
• W1514558457 doi "https://doi.org/10.1111/j.1600-0609.2011.01637.x" @default.
• W1514558457 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21535160" @default.
• W1514558457 hasPublicationYear "2011" @default.
• W1514558457 type Work @default.
• W1514558457 sameAs 1514558457 @default.
• W1514558457 citedByCount "36" @default.
• W1514558457 countsByYear W15145584572012 @default.
• W1514558457 countsByYear W15145584572013 @default.
• W1514558457 countsByYear W15145584572014 @default.
• W1514558457 countsByYear W15145584572015 @default.
• W1514558457 countsByYear W15145584572016 @default.
• W1514558457 countsByYear W15145584572017 @default.
• W1514558457 countsByYear W15145584572019 @default.
• W1514558457 countsByYear W15145584572020 @default.
• W1514558457 countsByYear W15145584572021 @default.
• W1514558457 countsByYear W15145584572022 @default.
• W1514558457 crossrefType "journal-article" @default.
• W1514558457 hasAuthorship W1514558457A5003934490 @default.
• W1514558457 hasAuthorship W1514558457A5015364051 @default.
• W1514558457 hasAuthorship W1514558457A5015623446 @default.
• W1514558457 hasAuthorship W1514558457A5027543943 @default.
• W1514558457 hasAuthorship W1514558457A5031444581 @default.
• W1514558457 hasAuthorship W1514558457A5031769736 @default.
• W1514558457 hasAuthorship W1514558457A5034008882 @default.
• W1514558457 hasAuthorship W1514558457A5037131671 @default.
• W1514558457 hasAuthorship W1514558457A5045455980 @default.
• W1514558457 hasAuthorship W1514558457A5046844133 @default.
• W1514558457 hasAuthorship W1514558457A5060416371 @default.
• W1514558457 hasAuthorship W1514558457A5064549322 @default.
• W1514558457 hasAuthorship W1514558457A5084596816 @default.
• W1514558457 hasAuthorship W1514558457A5090042377 @default.
• W1514558457 hasConcept C126322002 @default.
• W1514558457 hasConcept C141071460 @default.
• W1514558457 hasConcept C2777408962 @default.
• W1514558457 hasConcept C2777583451 @default.
• W1514558457 hasConcept C2778729363 @default.
• W1514558457 hasConcept C2908647359 @default.
• W1514558457 hasConcept C2911091166 @default.
• W1514558457 hasConcept C2993416501 @default.
• W1514558457 hasConcept C3019892230 @default.
• W1514558457 hasConcept C535046627 @default.
• W1514558457 hasConcept C71924100 @default.
• W1514558457 hasConcept C99454951 @default.
• W1514558457 hasConceptScore W1514558457C126322002 @default.
• W1514558457 hasConceptScore W1514558457C141071460 @default.
• W1514558457 hasConceptScore W1514558457C2777408962 @default.
• W1514558457 hasConceptScore W1514558457C2777583451 @default.
• W1514558457 hasConceptScore W1514558457C2778729363 @default.
• W1514558457 hasConceptScore W1514558457C2908647359 @default.
• W1514558457 hasConceptScore W1514558457C2911091166 @default.
• W1514558457 hasConceptScore W1514558457C2993416501 @default.
• W1514558457 hasConceptScore W1514558457C3019892230 @default.
• W1514558457 hasConceptScore W1514558457C535046627 @default.
• W1514558457 hasConceptScore W1514558457C71924100 @default.
• W1514558457 hasConceptScore W1514558457C99454951 @default.
• W1514558457 hasIssue "2" @default.
• W1514558457 hasLocation W15145584571 @default.

• next